Kazyaka/iStock via Getty Images
As Aurora Cannabis (NASDAQ:ACB) gears up to unveil its Q3 earnings report on Thursday, February 8th, before the market opens, investors remain fixated on the company’s reliance on medical marijuana to stabilize its profits.
Anticipated figures suggest that analysts are projecting an EPS of -$0.01 on revenues of $47.15M.
Speculation has emerged over the past 3 months with no upward adjustments to EPS estimates, and 1 downward revision. Moreover, revenue estimates have witnessed 2 upward and 2 downward revisions, hinting at the tug of war over future performance.
The Alberta-based cannabis titan posted C$63.4M in net revenue for Q2 FY24, reflecting a solid ~30% Year-on-Year growth. Noteworthy is their shift to C$3.4M in positive adjusted EBITDA, largely propelled by its lucrative medical cannabis segment.
Contrarily, Aurora (ACB) has fallen short of EPS estimates during five of the last seven quarters, including the last four consecutive quarters.
Expressing discouragement, shares have plummeted -14.34% since the dawn of 2024 and a hefty -59.74% over the past 12 months.
